Primary Immunodeficiency is caused by inherent defects of the immune system. It results in recurrent, severe or unusual infections. Intravenous immunoglobulin (IVIG) treatment can preserve organ function, improve quality of life, prevent infection-related death and increase lifespan.
This IVIG toolkit is a resource for educating payers and regulators responsible for coverage determinations and aid physicians in the safe, effective and appropriate use of IVIG for patients with primary immunodeficiency diseases (PIDD). This toolkit has been approved by the AAAAI Board of Directors, and endorsed by the Clinical Immunology Society (CIS) and the Immune Deficiency Foundation (IDF).
Eight guiding principles for safe, effective and appropriate use of IVIG (PDF)
Guidelines for the site of care for administration of IGIV therapy (PDF)
AAAAI Work Group Report: The Appropriate Use of Intravenously Administered Immunoglobulin (IGIV) (PDF)
"Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy Asthma & Immunology," published as a supplement to The Journal of Allergy and Clinical Immunology in April, 2006 (PDF)